- Trials with a EudraCT protocol (94)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
94 result(s) found for: Inoculation.
Displaying page 1 of 5.
EudraCT Number: 2017-004582-27 | Sponsor Protocol Number: RSV-MVA-013 | Start Date*: 2018-07-23 | |||||||||||
Sponsor Name:Bavarian Nordic A/S | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blinded, Placebo-controlled Trial to assess the Safety, Immunogenicity, and Efficacy of the recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infectio... | |||||||||||||
Medical condition: Upper and lower respiratory tract infections caused by Respiratory Syncytical Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000944-13 | Sponsor Protocol Number: GEN-004-002 | Start Date*: 2014-07-30 | |||||||||||
Sponsor Name:Genocea Biosciences, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intran... | |||||||||||||
Medical condition: Pneumococcal Nasal Carriage | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004634-26 | Sponsor Protocol Number: 4896 | Start Date*: 2015-05-20 | |||||||||||
Sponsor Name:Royal Liverpool University Hospital [...] | |||||||||||||
Full Title: The Effect of Live Attenuated Influenza Vaccine (LAIV) on Experimental Human Pneumococcal Colonisation (EHPC) Study | |||||||||||||
Medical condition: Pneumococcal colonisation post inoculation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003347-28 | Sponsor Protocol Number: MK-1654-005 | Start Date*: 2019-10-03 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp | |||||||||||||
Full Title: A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated with Experimental Respiratory Syncytial Virus. | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000596-87 | Sponsor Protocol Number: ACTIVATE | Start Date*: 2017-05-26 | ||||||||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | ||||||||||||||||||
Full Title: A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS OF THE ELDERLY: THE ACTIVATE TRIAL | ||||||||||||||||||
Medical condition: Vaccination for infection prevention | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005041-41 | Sponsor Protocol Number: 53718678RSV2001 | Start Date*: 2015-04-24 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the antiviral activity, safety, and pharmacokinetics of repeated doses of orally administered JNJ-53718678 against Respi... | |||||||||||||
Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005929-49 | Sponsor Protocol Number: VX11-787-101 | Start Date*: 2012-02-20 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus | |||||||||||||
Medical condition: Influenza A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004137-21 | Sponsor Protocol Number: 78591.041.21 | Start Date*: 2021-10-28 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection – a human challenge study | ||
Medical condition: respiratory syncytial virus infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000574-35 | Sponsor Protocol Number: VIS410-201 | Start Date*: 2015-04-27 | |||||||||||
Sponsor Name:Visterra, Inc. | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects after a Viral Ino... | |||||||||||||
Medical condition: Influenza A (H1N1) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003089-34 | Sponsor Protocol Number: HND-IM-011 | Start Date*: 2011-09-06 | |||||||||||||||||||||
Sponsor Name:Chr. Hansen A/S | |||||||||||||||||||||||
Full Title: The effect for Lactobacillus paracasei subsp. paracasei, L. casei 431® on immune response to influenza vaccination in healthy adult volunteers - a multi-center, randomized, placebo-controlled, par... | |||||||||||||||||||||||
Medical condition: effect of probiotics on the immune response to seasonal influenza vaccination in healthy adults | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001103-31 | Sponsor Protocol Number: AIT02-2001/DMID14-005 | Start Date*: 2015-07-10 | |||||||||||
Sponsor Name:Autoimmune Technologies, LLC | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects wh... | |||||||||||||
Medical condition: Influenza A infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002965-35 | Sponsor Protocol Number: GID18 | Start Date*: 2005-09-15 | |||||||||||
Sponsor Name:Sanofi Pasteur SA | |||||||||||||
Full Title: Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children | |||||||||||||
Medical condition: Vaccination of healthy children aged 6 to 35 months and 3 to 8 years (2 doses at a 28 day-interval) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002147-10 | Sponsor Protocol Number: FLU-MARK | Start Date*: 2011-09-21 | ||||||||||||||||
Sponsor Name:Institute for Biomedical Aging Research | ||||||||||||||||||
Full Title: Influenza vaccination in old age: Immunological and biogerontological characterization of responders and non-responders | ||||||||||||||||||
Medical condition: This study will analyze cellular and humoral immune responses after seasonal vaccination against influenza. Healthy adults are vaccinated with a licensed trivalent inactivated vaccine without adjuv... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005645-38 | Sponsor Protocol Number: TBEB08 | Start Date*: 2008-01-17 | |||||||||||
Sponsor Name:Clinical Institute of Virology, Medical University of Vienna | |||||||||||||
Full Title: B-cell memory and humoral immune response after primary immunization against tick borne encephalitis (TBE) in the elderly | |||||||||||||
Medical condition: This study will investigate immunity against tick-borne encephalitis (TBE) following primary TBE vaccination in healthy volunteers 18-30 years or > 60 years who fulfill the local criteria for TBE v... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001714-24 | Sponsor Protocol Number: BTA798-CL2-001 | Start Date*: 2008-06-18 |
Sponsor Name:Biota Scientific Management Pty Ltd | ||
Full Title: A Phase II, Double-Blind Placebo-Controlled Study to Determine the Prophylactic Efficacy of Oral BTA798 in an Experimental Rhinovirus Challenge Model | ||
Medical condition: BTA798 is an investigational drug being developed as a potential agent for treatment and prevention of the common cold. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-001504-37 | Sponsor Protocol Number: 30/2006/O/Sper | Start Date*: 2006-05-18 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS ACHN-IL2 MIXED TO AUTOLOGOUS TUMOR CELLS CT-AUT IN PATIENTS WITH METASTATIC RENAL CARCINOMA. | |||||||||||||
Medical condition: Metastatic Kidney Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006209-83 | Sponsor Protocol Number: 2011/198/HP | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU - Hôpitaux de Rouen | |||||||||||||
Full Title: Evaluation of the Immune Response against Neisseria meningitidis B:14, P1-7,16 in subjects inoculated by MenBVac ® vaccine. | |||||||||||||
Medical condition: Immunogenic Study, in french children living in the region of Normandy, France, after vaccination for B:14:P1.7,16, to evaluate the longer-term persistence of antibodies against B:14P1.7,16. bacter... | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006268-27 | Sponsor Protocol Number: 2011/199/HP | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU - Hôpitaux de Rouen | |||||||||||||
Full Title: Evaluation of the Immune Response against Neisseria meningitidis B:14,P1-7,16 in subjects inoculated by MenBVac (R) vaccine. | |||||||||||||
Medical condition: Immunogenic Study, in french children living in the region of Normandy, France, after vaccination for B:14,P1-7,16 bacterial strain. | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002401-23 | Sponsor Protocol Number: GID15 | Start Date*: 2005-10-06 | |||||||||||
Sponsor Name:Sanofi Pasteur SA | |||||||||||||
Full Title: Immunogenicity of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with Intramuscular Vaccination with Vaxigrip® in Adults. | |||||||||||||
Medical condition: Annual vaccination of healthy adult (18-60 years) for 3 consecutive years. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001107-20 | Sponsor Protocol Number: MDT-637-CP-201 | Start Date*: 2013-08-02 | |||||||||||
Sponsor Name:MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd. | |||||||||||||
Full Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b) | |||||||||||||
Medical condition: RSV Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
